Robert F. Schwabe, MD

  • Professor of Medicine
Profile Headshot

Profile Navigation

Overview

Dr. Robert Schwabe is a Professor of Medicine and serves as the Director of the NIH P30-funded Digestive and Liver Disease Research Center at Columbia University (CU-DLDRC). The Schwabe lab focuses on two key research areas: (i) liver fibrosis (30% of the adult global population now has metabolic-associated steatotic liver disease (MASLD) and is at risk for liver fibrosis); and (ii) liver cancer, the third leading cause of cancer mortality worldwide. Dr. Schwabe's research combines mouse modeling, human data, Systems Biology approaches and in vivo CRISPRi/a screens to understand cell-cell communication, novel vulnerabilities and therapy resistance in chronic liver disease and liver cancer. As Director of the CU-DLDRC, Dr. Schwabe seeks to deepen the understanding of digestive disease mechanisms, increase basic-clinical collaboration, advance treatment options and connect with the national digestive disease research landscape.

Academic Appointments

  • Professor of Medicine

Gender

  • Male

Research

The Schwabe combines state-of-the-art mouse models with patient samples, Systems Biology approaches and preclinical studies to elucidate and target mechanisms of fibrosis and liver cancer development and progression. (i) To understand the contribution of fibroblasts in the development of liver fibrosis, MASLD and liver cancer, our lab has generated tools for hepatic stellate cell and fibroblast-selective labeling, manipulation and depletion. Using these tools, we have described dual roles of hepatic stellate cells: They serve as key contributors to metabolic homeostasis in the healthy liver but turn into a pathogenic cell type that promotes the development of fibrosis in the chronically injured liver; and can switch between these states. Our research in liver fibrosis and fibroblast biology seeks to further extend the novel concept that hepatic stellate cells have a key role in homeostasis of the healthy liver, defending against infections, metabolic imbalance, injury and cancer development. (ii) Novel tumor cell-specific in vivo CRISPRi and CRISPRa methods allow us to identify novel druggable targets and transcriptional programs that maintain specific tumor states or resistance. These approaches allow for rapid in vivo screens of hundreds to thousands of candidates without time-consuming mouse breeding. Moreover, they can be used for combinatorial screens to identify targets for combination therapy; as well as tumor cell interactions with cancer-associated fibroblasts or the immune system. Together, these efforts have led to novel therapeutic concepts and multimodal therapies (with FDA-approved drugs) that potently extend survival in preclinical models of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), decreasing fibroblast-mediated resistance or increasing immune cell recognition. Our ongoing research in liver cancer (HCC, CCA, and pancreatic liver metastasis) seeks to deepen our understanding of master regulators that mediate tumor growth, immune exclusion, and therapy-resistant tumor states, with the long-term goal of developing multimodal therapies that achieve long-term control or eradication of liver cancer.

Selected Publications

Saito, Y., Yin, D., Kubota, N., Wang, X., Filliol, A., Remotti, H., Nair, A., Fazlollahi, L., Hoshida, Y., Tabas, I., Wangensteen, K. J., & Schwabe, R. F. (2023). A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology, 164(7), 1279–1292. https://doi.org/10.1053/j.gastro.2023.02.043

Filliol, A., Saito, Y., Nair, A., Dapito, D. H., Yu, L. X., Ravichandra, A., Bhattacharjee, S., Affo, S., Fujiwara, N., Su, H., Sun, Q., Savage, T. M., Wilson-Kanamori, J. R., Caviglia, J. M., Chin, L., Chen, D., Wang, X., Caruso, S., Kang, J. K., Amin, A. D., … Schwabe, R. F. (2022). Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature, 610(7931), 356–365. https://doi.org/10.1038/s41586-022-05289-6

Affo, S., Nair, A., Brundu, F., Ravichandra, A., Bhattacharjee, S., Matsuda, M., Chin, L., Filliol, A., Wen, W., Song, X., Decker, A., Worley, J., Caviglia, J. M., Yu, L., Yin, D., Saito, Y., Savage, T., Wells, R. G., Mack, M., Zender, L., … Schwabe, R. F. (2021). Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer cell, 39(6), 866–882.e11. https://doi.org/10.1016/j.ccell.2021.03.012

Bhattacharjee, S., Hamberger, F., Ravichandra, A., Miller, M., Nair, A., Affo, S., Filliol, A., Chin, L., Savage, T. M., Yin, D., Wirsik, N. M., Mehal, A., Arpaia, N., Seki, E., Mack, M., Zhu, D., Sims, P. A., Kalluri, R., Stanger, B. Z., Olive, K. P., … Schwabe, R. F. (2021). Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. The Journal of clinical investigation, 131(11), e146987. https://doi.org/10.1172/JCI146987

Back to top